Annoviant Awarded $1.85M SBIR Phase II Grant from the National Institutes of Health

Funding will help drive commercialization of next-generation pulmonary valve conduit for pediatric patients

Annoviant LLC, formerly TGen Tech LLC, today announced that it has been awarded a grant of $1.85 million for two years by the National Institutes of Health (NIH) to help further its development and commercialization of the TxGuard™ pulmonary-valved conduit. This is a continuation of the Phase I Small Business Technology Transfer (STTR) grant the company received in 2019.

The new conduit represents breakthrough technology in conduit replacements for the treatment of congenital heart disease (CHD). Tailored largely toward pediatric patients, the device is designed to resist early degeneration and allows regeneration with host cells, enabling the device to grow with children.

CHD affects approximately 40,000 newborns each year in the U.S. Valve and conduit replacements are needed for absent pulmonary valve, aortic stenosis (Konno procedure, Ross, procedure), double outlet right ventricle (Rastelli operation), extracardiac conduit (Fontan operation), and pulmonary valve replacement (Tetralogy of Fallot).

“We’re extremely pleased to receive this grant, and we are grateful for the National Heart, Lung, and Blood Institute’s financial support,” said Ajay Houde, Ph.D., MBA, co-founder and CEO, Annoviant. “The grant funding will enable us to address the clinical and cost challenges associated with treating CHD in children.”

The primary issues currently observed with commercial devices are (a) calcification; (b) thrombosis; and (c) infection. Annually, 40,000 (U.S.) and 1.3 million (global) children are born with CHD, resulting in 4%-6% of neonatal deaths. According to the Centers for Disease Control and Prevention (CDC), there are about 2.9 million CHD patients in the U.S.

Pediatric patients with CHD typically undergo 3 to 5 cardiovascular surgeries over their lifetimes with an estimated total cost of $5.61 billion1 to the U.S. healthcare industry for treatment of CHD patients.

The TxGuard “scaffolding” exhibits clinical advantages over commercial products, specifically its cutting-edge qualities that make it resistant to calcification (plaques), thrombosis, and infection. Its ability to regenerate and grow with patients also is a significant distinguishing benefit.

 

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy